Specialists say getting these bodyweight-loss medicines via alternate routes is often risky, because neither Novo nor Eli Lilly market their medicine to other producers.2). Tirzepatide’s capability to co-administer GIP and GLP-1 has synergistic results on minimizing entire body bodyweight, foods use, and Excess fat mass in animal products, which